Kailera Therapeutics, Inc.
$20.68-1.6%1Y-19.2%
Mentions · last 7 days
39
Price updated 10m ago·X counts updated 23h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $KLRA.
Biotechnology
IBB +2.9% on GLP-1 pipeline momentum and MRNA's post-9-0 FDA vote continuation — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
Top industry ETF
$IBBiShares Biotechnology ETF
+16.3%YTD
+49.2%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-16.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-24.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
41.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
-0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 26, 2026$-3650.00$-0.78-470867.7%
Q1 2026May 26, 2026$-0.67$-0.78+13.5%
Next earningsTue, Aug 25·consensus EPS $-0.74
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.67$-68.3M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$3.61-$4.26 – -$2.940
FY27$0$0 – $0-$3.84-$4.53 – -$2.800
FY28$0$0 – $0-$3.41-$5.30 – -$2.010
FY29$138.9M$138.9M – $138.9M-$3.84-$3.84 – -$3.845
FY30$522.1M$522.1M – $522.1M-$2.68-$2.68 – -$2.683
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 89.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
3New insider — initial holdingsJul 83
AI summary
8-KCharter amendmentApr 208-K — Item 5.03: Charter amendment · Item 8.01: Other event
+ 27 other (17 3s · 1 10-Q · 1 earnings 8-K · 1 S-8) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To WinWhy Is Kailera Therapeutics Stock Falling Tuesday?Kailera's GLP-1 drug meets main goal of late-stage trialsKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerBiotech ETF Index Surges 10% After Rebalance
In themes
Explore the broader themes this ticker is being talked about under.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 1 · last 7 days